

COPY

DOCKET NO. 1161.1027-064

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

In re Application of:

Maria S. Gawryl, Robert A. Houtchens and William R. Light

Application No.:

10/018,599

Filed (371(c)):

May 22, 2002

Confirmation No.:

8372

For:

PRESERVING A HEMOGLOBIN BLOOD SUBSTITUTE WITH A TRANSPARENT OVERWRAP

The owner. Biopure Corporation of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent Nos. 6,288,027 and 6,271,351. The owner hereby agrees that any patent so granted on the instant application shell be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer in the event that it later: expires for fallure to pay a maintenance fac, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The terminal disclaimer fee under 37 CFR 1.20(d) is enclosed.

The undersigned is empowered to act on behalf of the owner.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may joopardize the validity of the application or any patent issued thereon.

1 April 05

Carl W. Rausch

Typed or printed name

Biopure Corporation



Docket	No	1161.10	27-064

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Appli	cation N	o./Patont No.: 10/018,599	Filed (371(c)): May 22, 2002
For:P	RESERY	VING A HEMOGLOBIN BLOOD	SUBSTITUTE WITH A TRANSPARENT OVERWRAP
		Biopure Corporation (Name of Analgaca)	B Corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, suc.)
s : #te\$	that it is	·	
A.	[X]	the ussignee of the entire right,	title and interest in the patent application identified above; or
В.	1 1	an assignee together with [ubove.] of the entire right, title and interest in the patent application identified
The ri	ght, title	and interest of the above-named as	ssignee in the patent application identified above is established by virtue of
A. [X]	An as	signment from the inventor(s) of the rademark Office at Roel 0129	re patent application identified above. The assignment was recorded in the Pute 229 . Frame <u>0553-0556</u> , or a copy thereof is attached.
OR			*
B.[]	A cha	in of title from the inventor(s) of th	s patent application identified above, to the current assignee as shown below:
	1.		To: the United States Patent and Trademark Office at . or a copy thereof is attached.
	2.		To:To:, or a copy thereof is attached.
	3.	From:	то:
			the United States Patent and Trademark Office at, or a copy thereof is attached.
	[] A	dditional documents in the chain of	fittle are listed on a supplemental sheet.
fbe un	dersigned	(whose title is supplied below) is	authorized to act on behalf of the assignee.
ignatu	re:	I af W	[Muself
Vame:_		Carl W. Rausch	
itle:		Cofounder and Vice Chairman ar	nd Chiaf Technology Officer
ate:		1 April 05	•

@PPDetkippt:UDMA/MHODMA/HBRR05(iMssngs)\$370[4];